Skip to main content
Top
Published in: BMC Gastroenterology 1/2009

Open Access 01-12-2009 | Research article

Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002

Authors: Michael Hermansson, Anders Ekedahl, Jonas Ranstam, Thomas Zilling

Published in: BMC Gastroenterology | Issue 1/2009

Login to get access

Abstract

Background

Despite a decreasing incidence of peptic ulcer disease, most previous studies report a stabile incidence of ulcer complications. We wanted to investigate the incidence of peptic ulcer complications in Sweden before and after the introduction of the proton pump inhibitors (PPI) in 1988 and compare these data to the sales of non-steroid anti-inflammatory drugs (NSAID) and acetylsalicylic acid (ASA).

Methods

All cases of gastric and duodenal ulcer complications diagnosed in Sweden from 1974 to 2002 were identified using the National hospital discharge register. Information on sales of ASA/NSAID was obtained from the National prescription survey.

Results

When comparing the time-periods before and after 1988 we found a significantly lower incidence of peptic ulcer complications during the later period for both sexes (p < 0.001). Incidence rates varied from 1.5 to 7.8/100000 inhabitants/year regarding perforated peptic ulcers and from 5.2 to 40.2 regarding peptic ulcer bleeding. The number of sold daily dosages of prescribed NSAID/ASA tripled from 1975 to 2002. The number of prescribed sales to women was higher than to males. Sales of low-dose ASA also increased. The total volume of NSAID and ASA, i.e. over the counter sale and sold on prescription, increased by 28% during the same period.

Conclusion

When comparing the periods before and after the introduction of the proton pump inhibitors we found a significant decrease in the incidence of peptic ulcer complications in the Swedish population after 1988 when PPI were introduced on the market. The cause of this decrease is most likely multifactorial, including smoking habits, NSAID consumption, prevalence of Helicobacter pylori and the introduction of PPI. Sales of prescribed NSAID/ASA increased, especially in middle-aged and elderly women. This fact seems to have had little effect on the incidence of peptic ulcer complications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hermansson M, Stael von Holstein C, Zilling T: Peptic ulcer perforation before and after the introduction of H2-receptor blockers and proton pump inhibitors. Scand J Gastroenterol. 1997, 32 (6): 523-529. 10.3109/00365529709025093.CrossRefPubMed Hermansson M, Stael von Holstein C, Zilling T: Peptic ulcer perforation before and after the introduction of H2-receptor blockers and proton pump inhibitors. Scand J Gastroenterol. 1997, 32 (6): 523-529. 10.3109/00365529709025093.CrossRefPubMed
2.
go back to reference Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160 (14): 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed Hernandez-Diaz S, Rodriguez LA: Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000, 160 (14): 2093-2099. 10.1001/archinte.160.14.2093.CrossRefPubMed
3.
go back to reference Hippisley-Cox J, Coupland C, Logan R: Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Bmj. 2005, 331 (7528): 1310-1316. 10.1136/bmj.331.7528.1310.CrossRefPubMedPubMedCentral Hippisley-Cox J, Coupland C, Logan R: Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Bmj. 2005, 331 (7528): 1310-1316. 10.1136/bmj.331.7528.1310.CrossRefPubMedPubMedCentral
4.
go back to reference Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002, 359 (9300): 14-22. 10.1016/S0140-6736(02)07273-2.CrossRefPubMed Huang JQ, Sridhar S, Hunt RH: Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002, 359 (9300): 14-22. 10.1016/S0140-6736(02)07273-2.CrossRefPubMed
5.
go back to reference Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997, 112 (3): 683-689. 10.1053/gast.1997.v112.pm9041228.CrossRefPubMed Lanas A, Serrano P, Bajador E, Esteva F, Benito R, Sainz R: Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 1997, 112 (3): 683-689. 10.1053/gast.1997.v112.pm9041228.CrossRefPubMed
6.
go back to reference Langman MJ: Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?. Pharmacoepidemiol Drug Saf. 2001, 10 (1): 13-19. 10.1002/pds.561.CrossRefPubMed Langman MJ: Ulcer complications associated with anti-inflammatory drug use. What is the extent of the disease burden?. Pharmacoepidemiol Drug Saf. 2001, 10 (1): 13-19. 10.1002/pds.561.CrossRefPubMed
7.
go back to reference Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997, 8 (1): 18-24. 10.1097/00001648-199701000-00003.CrossRefPubMed Gutthann SP, Garcia Rodriguez LA, Raiford DS: Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology. 1997, 8 (1): 18-24. 10.1097/00001648-199701000-00003.CrossRefPubMed
8.
go back to reference Slattery J, Warlow CP, Shorrock CJ, Langman MJ: Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin–analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995, 37 (4): 509-511. 10.1136/gut.37.4.509.CrossRefPubMedPubMedCentral Slattery J, Warlow CP, Shorrock CJ, Langman MJ: Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin–analysis of gastrointestinal bleeding during the UK-TIA trial. Gut. 1995, 37 (4): 509-511. 10.1136/gut.37.4.509.CrossRefPubMedPubMedCentral
9.
go back to reference Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P: Prophylactic aspirin and risk of peptic ulcer bleeding. Bmj. 1995, 310 (6983): 827-830.CrossRefPubMedPubMedCentral Weil J, Colin-Jones D, Langman M, Lawson D, Logan R, Murphy M, Rawlins M, Vessey M, Wainwright P: Prophylactic aspirin and risk of peptic ulcer bleeding. Bmj. 1995, 310 (6983): 827-830.CrossRefPubMedPubMedCentral
10.
go back to reference Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000, 95 (9): 2218-2224.CrossRefPubMed Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, Olsen JH: Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000, 95 (9): 2218-2224.CrossRefPubMed
11.
go back to reference Higham J, Kang JY, Majeed A: Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002, 50 (4): 460-464. 10.1136/gut.50.4.460.CrossRefPubMedPubMedCentral Higham J, Kang JY, Majeed A: Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut. 2002, 50 (4): 460-464. 10.1136/gut.50.4.460.CrossRefPubMedPubMedCentral
12.
go back to reference Janik J, Chwirot P: Perforated peptic ulcer–time trends and patterns over 20 years. Med Sci Monit. 2000, 6 (2): 369-372.PubMed Janik J, Chwirot P: Perforated peptic ulcer–time trends and patterns over 20 years. Med Sci Monit. 2000, 6 (2): 369-372.PubMed
13.
go back to reference Paimela H, Tuompo PK, Perakyl T, Saario I, Hockerstedt K, Kivilaakso E: Peptic ulcer surgery during the H2-receptor antagonist era: a population-based epidemiological study of ulcer surgery in Helsinki from 1972 to 1987. Br J Surg. 1991, 78 (1): 28-31. 10.1002/bjs.1800780110.CrossRefPubMed Paimela H, Tuompo PK, Perakyl T, Saario I, Hockerstedt K, Kivilaakso E: Peptic ulcer surgery during the H2-receptor antagonist era: a population-based epidemiological study of ulcer surgery in Helsinki from 1972 to 1987. Br J Surg. 1991, 78 (1): 28-31. 10.1002/bjs.1800780110.CrossRefPubMed
14.
go back to reference Walt R, Katschinski B, Logan R, Ashley J, Langman M: Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet. 1986, 1 (8479): 489-492. 10.1016/S0140-6736(86)92940-5.CrossRefPubMed Walt R, Katschinski B, Logan R, Ashley J, Langman M: Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet. 1986, 1 (8479): 489-492. 10.1016/S0140-6736(86)92940-5.CrossRefPubMed
15.
go back to reference Christensen S, Riis A, Norgaard M, Thomsen RW, Sorensen HT: Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Aliment Pharmacol Ther. 2007, 25 (8): 907-912.CrossRefPubMed Christensen S, Riis A, Norgaard M, Thomsen RW, Sorensen HT: Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Aliment Pharmacol Ther. 2007, 25 (8): 907-912.CrossRefPubMed
16.
go back to reference Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B: [Reliability of the hospital registry. The diagnostic data are better than their reputation]. Lakartidningen. 1994, 91 (7): 603-595. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B: [Reliability of the hospital registry. The diagnostic data are better than their reputation]. Lakartidningen. 1994, 91 (7): 603-595.
17.
go back to reference Gustavsson S, Kelly KA, Melton LJ, Zinsmeister AR: Trends in peptic ulcer surgery. A population-based study in Rochester, Minnesota, 1956–1985. Gastroenterology. 1988, 94 (3): 688-694.CrossRefPubMed Gustavsson S, Kelly KA, Melton LJ, Zinsmeister AR: Trends in peptic ulcer surgery. A population-based study in Rochester, Minnesota, 1956–1985. Gastroenterology. 1988, 94 (3): 688-694.CrossRefPubMed
18.
go back to reference Svanes C, Lie RT, Kvale G, Svanes K, Soreide O: Incidence of perforated ulcer in western Norway, 1935–1990: cohort- or period-dependent time trends?. Am J Epidemiol. 1995, 141 (9): 836-844.PubMed Svanes C, Lie RT, Kvale G, Svanes K, Soreide O: Incidence of perforated ulcer in western Norway, 1935–1990: cohort- or period-dependent time trends?. Am J Epidemiol. 1995, 141 (9): 836-844.PubMed
19.
20.
go back to reference Lam SK, Byth K, Ng MM, Hui WM, McIntosh J, Piper DW: Perforated peptic ulcer in Hong Kong and New South Wales. J Gastroenterol Hepatol. 1992, 7 (5): 508-511. 10.1111/j.1440-1746.1992.tb01029.x.CrossRefPubMed Lam SK, Byth K, Ng MM, Hui WM, McIntosh J, Piper DW: Perforated peptic ulcer in Hong Kong and New South Wales. J Gastroenterol Hepatol. 1992, 7 (5): 508-511. 10.1111/j.1440-1746.1992.tb01029.x.CrossRefPubMed
21.
go back to reference Paimela H, Oksala NK, Kivilaakso E: Surgery for peptic ulcer today. A study on the incidence, methods and mortality in surgery for peptic ulcer in Finland between 1987 and 1999. Dig Surg. 2004, 21 (3): 185-191. 10.1159/000079654.CrossRefPubMed Paimela H, Oksala NK, Kivilaakso E: Surgery for peptic ulcer today. A study on the incidence, methods and mortality in surgery for peptic ulcer in Finland between 1987 and 1999. Dig Surg. 2004, 21 (3): 185-191. 10.1159/000079654.CrossRefPubMed
22.
go back to reference Christensen A, Bousfield R, Christiansen J: Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists. Ann Surg. 1988, 207 (1): 4-6. 10.1097/00000658-198801000-00002.CrossRefPubMedPubMedCentral Christensen A, Bousfield R, Christiansen J: Incidence of perforated and bleeding peptic ulcers before and after the introduction of H2-receptor antagonists. Ann Surg. 1988, 207 (1): 4-6. 10.1097/00000658-198801000-00002.CrossRefPubMedPubMedCentral
23.
go back to reference Makela J, Laitinen S, Kairaluoma MI: Complications of peptic ulcer disease before and after the introduction of H2-receptor antagonists. Hepatogastroenterology. 1992, 39 (2): 144-148.PubMed Makela J, Laitinen S, Kairaluoma MI: Complications of peptic ulcer disease before and after the introduction of H2-receptor antagonists. Hepatogastroenterology. 1992, 39 (2): 144-148.PubMed
24.
go back to reference Makela JT, Kiviniemi H, Ohtonen P, Laitinen SO: Factors that predict morbidity and mortality in patients with perforated peptic ulcers. Eur J Surg. 2002, 168 (8–9): 446-451.PubMed Makela JT, Kiviniemi H, Ohtonen P, Laitinen SO: Factors that predict morbidity and mortality in patients with perforated peptic ulcers. Eur J Surg. 2002, 168 (8–9): 446-451.PubMed
25.
go back to reference Canoy DS, Hart AR, Todd CJ: Epidemiology of duodenal ulcer perforation: a study on hospital admissions in Norfolk, United Kingdom. Dig Liver Dis. 2002, 34 (5): 322-327. 10.1016/S1590-8658(02)80124-4.CrossRefPubMed Canoy DS, Hart AR, Todd CJ: Epidemiology of duodenal ulcer perforation: a study on hospital admissions in Norfolk, United Kingdom. Dig Liver Dis. 2002, 34 (5): 322-327. 10.1016/S1590-8658(02)80124-4.CrossRefPubMed
26.
go back to reference Ohmann C, Imhof M, Ruppert C, Janzik U, Vogt C, Frieling T, Becker K, Neumann F, Faust S, Heiler K: Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol. 2005, 40 (8): 914-920. 10.1080/00365520510015809.CrossRefPubMed Ohmann C, Imhof M, Ruppert C, Janzik U, Vogt C, Frieling T, Becker K, Neumann F, Faust S, Heiler K: Time-trends in the epidemiology of peptic ulcer bleeding. Scand J Gastroenterol. 2005, 40 (8): 914-920. 10.1080/00365520510015809.CrossRefPubMed
27.
go back to reference Coggon D, Lambert P, Langman MJ: 20 years of hospital admissions for peptic ulcer in England and Wales. Lancet. 1981, 1 (8233): 1302-1304. 10.1016/S0140-6736(81)92470-3.CrossRefPubMed Coggon D, Lambert P, Langman MJ: 20 years of hospital admissions for peptic ulcer in England and Wales. Lancet. 1981, 1 (8233): 1302-1304. 10.1016/S0140-6736(81)92470-3.CrossRefPubMed
30.
go back to reference Jorgensen TG: Drug consumption before perforation of peptic ulcer. Br J Surg. 1977, 64 (4): 247-249. 10.1002/bjs.1800640406.CrossRefPubMed Jorgensen TG: Drug consumption before perforation of peptic ulcer. Br J Surg. 1977, 64 (4): 247-249. 10.1002/bjs.1800640406.CrossRefPubMed
31.
go back to reference Hawkey CJ: Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut. 2000, 46 (3): 310-311. 10.1136/gut.46.3.310.CrossRefPubMedPubMedCentral Hawkey CJ: Risk of ulcer bleeding in patients infected with Helicobacter pylori taking non-steroidal anti-inflammatory drugs. Gut. 2000, 46 (3): 310-311. 10.1136/gut.46.3.310.CrossRefPubMedPubMedCentral
32.
go back to reference Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA: The cohort effect and Helicobacter pylori. J Infect Dis. 1993, 168 (1): 219-221.CrossRefPubMed Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA: The cohort effect and Helicobacter pylori. J Infect Dis. 1993, 168 (1): 219-221.CrossRefPubMed
33.
go back to reference Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G: Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol. 1997, 25 (4): 583-586. 10.1097/00004836-199712000-00006.CrossRefPubMed Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G: Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol. 1997, 25 (4): 583-586. 10.1097/00004836-199712000-00006.CrossRefPubMed
34.
go back to reference Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM: Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol. 1997, 92 (9): 1480-1482.PubMed Roosendaal R, Kuipers EJ, Buitenwerf J, van Uffelen C, Meuwissen SG, van Kamp GJ, Vandenbroucke-Grauls CM: Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol. 1997, 92 (9): 1480-1482.PubMed
35.
go back to reference Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ: Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998, 12 (2): 135-140. 10.1046/j.1365-2036.1998.00288.x.CrossRefPubMed Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, Hawkey CJ: Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 1998, 12 (2): 135-140. 10.1046/j.1365-2036.1998.00288.x.CrossRefPubMed
36.
go back to reference Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, Thorhallsson E, Unge P: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996, 31 (8): 753-758. 10.3109/00365529609010347.CrossRefPubMed Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, Thorhallsson E, Unge P: Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol. 1996, 31 (8): 753-758. 10.3109/00365529609010347.CrossRefPubMed
37.
go back to reference Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998, 338 (11): 727-734. 10.1056/NEJM199803123381105.CrossRefPubMed Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, Yeomans ND: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998, 338 (11): 727-734. 10.1056/NEJM199803123381105.CrossRefPubMed
38.
go back to reference Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998, 338 (11): 719-726. 10.1056/NEJM199803123381104.CrossRefPubMed Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, Swannell AJ, Hawkey CJ: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med. 1998, 338 (11): 719-726. 10.1056/NEJM199803123381104.CrossRefPubMed
39.
go back to reference Vonkeman HE, Fernandes RW, Palen van der J, van Roon EN, Laar van de MA: Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther. 2007, 9 (3): R52-10.1186/ar2207.CrossRefPubMedPubMedCentral Vonkeman HE, Fernandes RW, Palen van der J, van Roon EN, Laar van de MA: Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Res Ther. 2007, 9 (3): R52-10.1186/ar2207.CrossRefPubMedPubMedCentral
40.
go back to reference Gisbert JP, Pajares JM: Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter. 2003, 8 (3): 159-167. 10.1046/j.1523-5378.2003.00139.x.CrossRefPubMed Gisbert JP, Pajares JM: Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter. 2003, 8 (3): 159-167. 10.1046/j.1523-5378.2003.00139.x.CrossRefPubMed
41.
go back to reference Reinbach DH, Cruickshank G, McColl KE: Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut. 1993, 34 (10): 1344-1347. 10.1136/gut.34.10.1344.CrossRefPubMedPubMedCentral Reinbach DH, Cruickshank G, McColl KE: Acute perforated duodenal ulcer is not associated with Helicobacter pylori infection. Gut. 1993, 34 (10): 1344-1347. 10.1136/gut.34.10.1344.CrossRefPubMedPubMedCentral
42.
go back to reference Kate V, Ananthakrishnan N, Badrinath S: Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br J Surg. 2001, 88 (8): 1054-1058. 10.1046/j.0007-1323.2001.01831.x.CrossRefPubMed Kate V, Ananthakrishnan N, Badrinath S: Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies. Br J Surg. 2001, 88 (8): 1054-1058. 10.1046/j.0007-1323.2001.01831.x.CrossRefPubMed
43.
go back to reference Debongnie JC, Wibin E, Timmermans M, Mairesse J, Dekoninck X: Are perforated gastroduodenal ulcers related to Helicobacter pylori infection?. Acta Gastroenterol Belg. 1995, 58 (2): 208-212.PubMed Debongnie JC, Wibin E, Timmermans M, Mairesse J, Dekoninck X: Are perforated gastroduodenal ulcers related to Helicobacter pylori infection?. Acta Gastroenterol Belg. 1995, 58 (2): 208-212.PubMed
44.
go back to reference Henriksson AE, Edman AC, Nilsson I, Bergqvist D, Wadstrom T: Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol. 1998, 33 (10): 1030-1033. 10.1080/003655298750026705.CrossRefPubMed Henriksson AE, Edman AC, Nilsson I, Bergqvist D, Wadstrom T: Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer. Scand J Gastroenterol. 1998, 33 (10): 1030-1033. 10.1080/003655298750026705.CrossRefPubMed
45.
go back to reference Matsukura N, Onda M, Tokunaga A, Kato S, Yoshiyuki T, Hasegawa H, Yamashita K, Tomtitchong P, Hayashi A: Role of Helicobacter pylori infection in perforation of peptic ulcer: an age- and gender-matched case-control study. J Clin Gastroenterol. 1997, 25 (Suppl 1): S235-239. 10.1097/00004836-199700001-00037.CrossRefPubMed Matsukura N, Onda M, Tokunaga A, Kato S, Yoshiyuki T, Hasegawa H, Yamashita K, Tomtitchong P, Hayashi A: Role of Helicobacter pylori infection in perforation of peptic ulcer: an age- and gender-matched case-control study. J Clin Gastroenterol. 1997, 25 (Suppl 1): S235-239. 10.1097/00004836-199700001-00037.CrossRefPubMed
46.
go back to reference Okan A, Tankurt E, Aslan BU, Akpinar H, Simsek I, Gonen O: Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study. J Gastroenterol Hepatol. 2003, 18 (1): 18-25. 10.1046/j.1440-1746.2003.02889.x.CrossRefPubMed Okan A, Tankurt E, Aslan BU, Akpinar H, Simsek I, Gonen O: Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: A case-control study. J Gastroenterol Hepatol. 2003, 18 (1): 18-25. 10.1046/j.1440-1746.2003.02889.x.CrossRefPubMed
47.
go back to reference Go MF: Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002, 16 (Suppl 1): 3-15. 10.1046/j.1365-2036.2002.0160s1003.x.CrossRefPubMed Go MF: Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment Pharmacol Ther. 2002, 16 (Suppl 1): 3-15. 10.1046/j.1365-2036.2002.0160s1003.x.CrossRefPubMed
48.
go back to reference Chu KM, Kwok KF, Law SY, Tuen HH, Tung PH, Branicki FJ, Wong J: Helicobacter pylori status and endoscopy follow-up of patients having a history of perforated duodenal ulcer. Gastrointest Endosc. 1999, 50 (1): 58-62. 10.1016/S0016-5107(99)70345-7.CrossRefPubMed Chu KM, Kwok KF, Law SY, Tuen HH, Tung PH, Branicki FJ, Wong J: Helicobacter pylori status and endoscopy follow-up of patients having a history of perforated duodenal ulcer. Gastrointest Endosc. 1999, 50 (1): 58-62. 10.1016/S0016-5107(99)70345-7.CrossRefPubMed
49.
go back to reference Ng EK, Lam YH, Sung JJ, Yung MY, To KF, Chan AC, Lee DW, Law BK, Lau JY, Ling TK, et al: Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg. 2000, 231 (2): 153-158. 10.1097/00000658-200002000-00001.CrossRefPubMedPubMedCentral Ng EK, Lam YH, Sung JJ, Yung MY, To KF, Chan AC, Lee DW, Law BK, Lau JY, Ling TK, et al: Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg. 2000, 231 (2): 153-158. 10.1097/00000658-200002000-00001.CrossRefPubMedPubMedCentral
50.
go back to reference Sebastian M, Chandran VP, Elashaal YI, Sim AJ: Helicobacter pylori infection in perforated peptic ulcer disease. Br J Surg. 1995, 82 (3): 360-362. 10.1002/bjs.1800820325.CrossRefPubMed Sebastian M, Chandran VP, Elashaal YI, Sim AJ: Helicobacter pylori infection in perforated peptic ulcer disease. Br J Surg. 1995, 82 (3): 360-362. 10.1002/bjs.1800820325.CrossRefPubMed
51.
go back to reference Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI: Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology. 2000, 11 (4): 434-439. 10.1097/00001648-200007000-00012.CrossRefPubMed Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI: Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology. 2000, 11 (4): 434-439. 10.1097/00001648-200007000-00012.CrossRefPubMed
Metadata
Title
Decreasing incidence of peptic ulcer complications after the introduction of the proton pump inhibitors, a study of the Swedish population from 1974–2002
Authors
Michael Hermansson
Anders Ekedahl
Jonas Ranstam
Thomas Zilling
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2009
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-9-25

Other articles of this Issue 1/2009

BMC Gastroenterology 1/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.